(Bold for FDA approved)
• PDE-5 is responsible for degradation of cyclic guanosine monophosphate (cGMP); cGMP produces smooth muscle relaxation in the corpus cavernosum and allows inflow of blood
• Inhibition of PDE-5 causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum
• Sildenafil has no direct relaxant effects on isolated human corpus cavernosum, and at recommended doses has no effect in the absence of sexual stimulation
• Maximum observed plasma concentrations are reached within 30–120 minutes (median 60 minutes) of oral dosing
• Headache
• Flushing
• Dyspepsia (indigestion, diarrhea)
• Sudden severe loss of vision and/or blurred vision
• Sudden decrease or loss of hearing, ringing in ears
• Erection that is painful or lasts longer than 4 hours
unusual
unusual
• Reduce dose to 25 mg
• Erectile dysfunction: 25–100 mg as needed, approximately 1 hour before sexual activity (Viagra)
• Pulmonary arterial hypertension (tablet and oral suspension): 5 mg or 20 mg 3 times a day, 4–6 hours apart
• Tablet 25 mg, 50 mg, 100 mg
• Injectable solution 10 mg/12.5 mL
• Safe
• No
• No adjustment for mild to moderate impairment
• For patients with severe impairment, consider a starting dose of 25 mg
• Consider a starting dose of 25 mg
• Elicits vasodilatory properties, resulting in mild and transient decreases in blood pressure
• Treatment for erectile dysfunction generally should not be instituted in men for whom sexual activity is inadvisable because of their underlying cardiovascular status
• There are no controlled clinical data on the safety or efficacy of sildenafil in patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; have resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg); or have cardiac failure or coronary artery disease causing unstable angina; use only with caution in these patients
• Use with caution in patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure
• Some patients may tolerate lower doses better
• Consider a starting dose of 25 mg
• Not recommended for use in pediatric patients
• Safety and efficacy have not been established
• Viagra is not indicated for use in women
• Controlled studies have not been conducted in pregnant women.
• Animal studies did not show teratogenicity or adverse developmental outcomes when administered during organogensis at doses up to 16 and 32 times the maximum recommended human dose
• Some drug is found in mother’s breast milk
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera